SOTERINIM Trademark
Trademark Overview
On Friday, August 4, 2023, a trademark application was filed for SOTERINIM with the United States Patent and Trademark Office. The USPTO has given the SOTERINIM trademark a serial number of 98117034. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Thursday, November 21, 2024. This trademark is owned by Pfizer Inc. The SOTERINIM trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
General Information
| Serial Number | 98117034 |
| Word Mark | SOTERINIM |
| Filing Date | Friday, August 4, 2023 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Thursday, November 21, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, May 14, 2024 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, August 11, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Pfizer Inc |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 100012192 |
| Party Name | Pfizer Inc |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 100012192 |
Trademark Events
| Event Date | Event Description |
| Tuesday, August 8, 2023 | NEW APPLICATION ENTERED |
| Friday, August 11, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, April 5, 2024 | ASSIGNED TO EXAMINER |
| Saturday, April 6, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, April 24, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, May 14, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, May 14, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 9, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Thursday, November 21, 2024 | SOU TEAS EXTENSION RECEIVED |
| Thursday, November 21, 2024 | SOU EXTENSION 1 GRANTED |
| Thursday, November 21, 2024 | SOU EXTENSION 1 FILED |
| Friday, November 22, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
